ABVC BIOPHARMA, INC. Total Revenue

• ABVC BIOPHARMA, INC. showed an increase of +234.3% in Total Revenue from 2023 to 2024.
• This data is from ABVC BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
• XBRL data for this metric is available from 2011 to 2024 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2012: $3.7 thousand | Q2 2012: $0.00 | Q4 2012: $7.0 thousand | Q1 2013: $761.00 | Q2 2013: $0.00 | Q4 2013: $0.00 | Q1 2014: $0.00 | Q2 2014: $0.00 | Q4 2014: $0.00 | Q1 2015: $0.00 | Q2 2015: $0.00 | Q4 2016: $70.0 thousand | Q2 2017: $90.0 thousand | Q2 2018: $3.2 thousand | Q3 2018: $747.00 | Q1 2019: $212.2 thousand | Q2 2019: $191.8 thousand | Q3 2019: $197.7 thousand | Q1 2020: $78.8 thousand | Q2 2020: $226.5 thousand | Q3 2020: $115.6 thousand | Q1 2021: $263.2 thousand | Q2 2021: $31.4 thousand | Q3 2021: $99.0 thousand | Q1 2022: $25.7 thousand | Q2 2022: $312.9 thousand | Q3 2022: $42.3 thousand | Q1 2023: $128.3 thousand | Q2 2023: $6.1 thousand | Q3 2023: $15.9 thousand | Q1 2024: $1.2 thousand | Q2 2024: $117.1 thousand | Q3 2024: $389.3 thousand | Q3 2025: $796.0 thousand.
• Over the full 13 years of available data (2011 to 2024), ABVC BIOPHARMA, INC.'s Total Revenue has grown by 15,874.6%.
• Historical annual values: Fiscal year 2024: $509.6 thousand | Fiscal year 2023: $152.4 thousand | Fiscal year 2022: $969.8 thousand | Fiscal year 2021: $355.8 thousand | Fiscal year 2020: $483.0 thousand | Fiscal year 2019: $701.7 thousand | Fiscal year 2018: $7.0 thousand | Fiscal year 2015: $3.4 thousand | Fiscal year 2014: $0.00 | Fiscal year 2014: $0.00 | Fiscal year 2013: $7.8 thousand | Fiscal year 2012: $5.7 thousand | Fiscal year 2011: $3.2 thousand.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026